Status:
COMPLETED
Observation Study of the Pharmacokinetics of Adductor Canal Block
Lead Sponsor:
The University of Hong Kong
Conditions:
Toxicity, Drug
Eligibility:
All Genders
18-80 years
Brief Summary
With the aging of the population, osteoarthritis of knees and hips become major orthopedic problems worldwide. Osteoarthritis of the knees and hips is associated with a significant pain problem and fu...
Detailed Description
After signing the consent form, participants will receive LIA with ACB using 5ml of 1.33% liposomal bupivacaine with 5ml of 0.9% normal saline. Participants will receive routine preoperative, intraop...
Eligibility Criteria
Inclusion
- ASA I-III
- Age 18-80 years old
- Scheduled for elective primary unilateral total knee replacement
- Chinese patients
- BMI \< 40
- Able to speak and understand Cantonese
- Able to provide informed oral and written consent
Exclusion
- Single-stage bilateral total knee replacement
- Complex primary total knee replacement requiring the use of stem/augment/constrained liner
- Surgeries with significant intraoperative complications which may alter rehabilitation protocol e.g. collateral ligament injury, fracture requiring fixation
- Known allergy to opioids, local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors
- History of chronic pain other than chronic knee pain
- History of immunosuppression
- Daily use of glucocorticoids
- Daily use of strong opioids (morphine, fentanyl, hydromorphone, ketobemidone, methadone, nicomorphine, oxycodone, or meperidine)
- History of severe heart disease (NYHA 2)
- Alcohol or drug abuse
- Impaired renal function, defined as preoperative serum creatinine level over 120 micromol/L
- Pre-existing neurological or muscular disorders
- Psychiatric illness or neurologic or psychiatric diseases potentially influencing pain perception
- Impaired or retarded mental state
- Difficulties in using patient-controlled analgesia (PCA)
- Pregnancy
- Local infection
- On immunosuppressants
- High BMI (\>=40)
- Patient refusal
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 4 2023
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04916392
Start Date
September 1 2020
End Date
April 4 2023
Last Update
December 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong